Trial Profile
A Prospective, Open-Label, Single Center, Pilot Study Investigating the Role of FDG-PET during Osimertinib Treatment to Predict the Responsiveness of Tumor Early in Patients with Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 19 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.